Semra Günay1, Ömür Alan2, Orhan Yalçın1, Aygen Türkmen3, Nihal Dizdar2. 1. Clinic of Breast and Endocrin Surgery, Ministry of Health Okmeydanı Training and Research Hospital, İstanbul, Turkey. 2. Clinic of Oncology, Ministry of Health Okmeydanı Training and Research Hospital, İstanbul, Turkey. 3. Clinic of Anesthesiology and Reanimation, Ministry of Health Okmeydanı Training and Research Hospital, İstanbul, Turkey.
Abstract
OBJECTIVE: To present our experience since November 2013, and case selection criteria for intraoperative boost radiotherapy (IObRT) that significantly reduces the local recurrence rate after breast conserving surgery in patients with breast cancer. MATERIAL AND METHODS: Patients who were suitable for IObRT were identified within the group of patients who were selected for breast conserving surgery at our breast council. A MOBETRON (mobile linear accelerator for IObRT) was used for IObRt during surgery. RESULTS: Patients younger than 60 years old with <3 cm invasive ductal cancer in one focus (or two foci within 2 cm), with a histologic grade of 2-3, and a high possibility of local recurrence were admitted for IObRT application. Informed consent was obtained from all participants. Lumpectomy and sentinel lymph node biopsy was performed and advancement flaps were prepared according to the size and inclination of the conus following evaluation of tumor size and surgical margins by pathology. Distance to the thoracic wall was measured, and a radiation oncologist and radiation physicist calculated the required dose. Anesthesia was regulated with slower ventilation frequency, without causing hypoxia. The skin and incision edges were protected, the field was radiated (with 6 MeV electron beam of 10 Gy) and the incision was closed. In our cases, there were no major postoperative surgical or early radiotherapy related complications. CONCLUSION: The completion of another stage of local therapy with IObRT during surgery positively effects sequencing of other treatments like chemotherapy, hormonotherapy and radiotherapy, if required. IObRT increases disease free and overall survival, as well as quality of life in breast cancer patients.
OBJECTIVE: To present our experience since November 2013, and case selection criteria for intraoperative boost radiotherapy (IObRT) that significantly reduces the local recurrence rate after breast conserving surgery in patients with breast cancer. MATERIAL AND METHODS:Patients who were suitable for IObRT were identified within the group of patients who were selected for breast conserving surgery at our breast council. A MOBETRON (mobile linear accelerator for IObRT) was used for IObRt during surgery. RESULTS:Patients younger than 60 years old with <3 cm invasive ductal cancer in one focus (or two foci within 2 cm), with a histologic grade of 2-3, and a high possibility of local recurrence were admitted for IObRT application. Informed consent was obtained from all participants. Lumpectomy and sentinel lymph node biopsy was performed and advancement flaps were prepared according to the size and inclination of the conus following evaluation of tumor size and surgical margins by pathology. Distance to the thoracic wall was measured, and a radiation oncologist and radiation physicist calculated the required dose. Anesthesia was regulated with slower ventilation frequency, without causing hypoxia. The skin and incision edges were protected, the field was radiated (with 6 MeV electron beam of 10 Gy) and the incision was closed. In our cases, there were no major postoperative surgical or early radiotherapy related complications. CONCLUSION: The completion of another stage of local therapy with IObRT during surgery positively effects sequencing of other treatments like chemotherapy, hormonotherapy and radiotherapy, if required. IObRTincreases disease free and overall survival, as well as quality of life in breast cancerpatients.
Entities:
Keywords:
Breast cancer; boost radiotherapy; intraoperative radiotherapy; local recurrence
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Krishna B Clough; Gabriel J Kaufman; Claude Nos; Ines Buccimazza; Isabelle M Sarfati Journal: Ann Surg Oncol Date: 2010-02-06 Impact factor: 5.344
Authors: Csaba Polgár; Erik Van Limbergen; Richard Pötter; György Kovács; Alfredo Polo; Jaroslaw Lyczek; Guido Hildebrandt; Peter Niehoff; Jose Luis Guinot; Ferran Guedea; Bengt Johansson; Oliver J Ott; Tibor Major; Vratislav Strnad Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Frederik Wenz; Samuele Massarut; Mohammed Keshtgar; Basil Hilaris; Christobel Saunders; Norman R Williams; Chris Brew-Graves; Tammy Corica; Mario Roncadin; Uta Kraus-Tiefenbacher; Marc Sütterlin; Max Bulsara; David Joseph Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: Melvin J Silverstein; Gerd Fastner; Sergio Maluta; Roland Reitsamer; Donald A Goer; Frank Vicini; David Wazer Journal: Ann Surg Oncol Date: 2014-08-20 Impact factor: 5.344